Tag Archives: ADC target

CDH6 ADC: Promising Results for Ovarian Cancer Treatment!

In March 2024, a preclinical study titled “Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models” was published in Molecular Cancer Therapeutics. This study demonstrated that Raludotatug Deruxtecan, developed by Daiichi Sankyo, is effective against human ovarian and kidney cancer models. Additionally, […]

Blog 2024-07-17

Tissue Factor (TF/CD142) – A Potential New Horizon for Pancreatic Cancer Therapy?

At the 2024 ASCO Annual Meeting, one of the highlights was the MRG004A-001 study conducted by Professor Yu Xianjun’s team, marking a milestone in the exploration of escalating doses of MRG004A, an ADC drug targeting tissue factor TF/CD142. Carried out in the United States and China, the study’s findings are significant. Among 12 evaluated pancreatic […]

Blog 2024-07-04

Nectin-4: A Promising Target in Antibody-Drug Conjugate (ADC) Therapy

During the 2024 ASCO conference, Professor Zhang Jian of Fudan University’s Cancer Hospital unveiled the Phase I/II clinical trial outcomes for 9MW2821, an ADC drug targeting Nectin-4, designed to combat advanced solid tumors. The drug demonstrated promising results, particularly in treating urothelial carcinoma, cervical cancer, esophageal cancer, and triple-negative breast cancer. Concurrently, CSPS showcased their […]

Blog 2024-06-13

Emerging Trends: ADC Drug Targets to Watch at ASCO 2024

The 2024 American Society of Clinical Oncology Annual Meeting (ASCO 2024) will take place in Chicago, USA, from May 31st to June 4th. As a major event in the cancer treatment community, it will reveal many important clinical research outcomes and the latest innovations. Antibody-drug conjugates (ADCs), which cleverly combine targeted antibody therapies with powerful […]

Blog 2024-05-23
Three types of Folate transporter

FRα/FOLR1 – Another Anti-cancer Target Fueled by the ADC

Folate receptor alpha (FRα), due to its differential expression in various tumor or cancer tissues compared to normal tissues, is considered an ideal druggable target. In the past, pharmaceutical companies have ventured into developing FRα-targeted therapies, including small molecule conjugates and monoclonal antibody drugs like Morphotek’s humanized monoclonal antibody farletuzumab, and Endocyte’s small molecule conjugate […]

Blog 2024-05-15
The structure of B7-H3 (transmembrane isoform)

Immune Checkpoint B7-H3: Exploring the Current Landscape of Targeted Therapies

In December 2023, GlaxoSmithKline (“GSK”) invested $1.71 billion to obtain the global exclusive rights for the development, production, and commercialization of HS-20093 from HANSON PHARAM (excluding mainland China, Hong Kong, Macau, and Taiwan). HS-20093 is a novel B7-H3 targeted antibody-drug conjugate (ADC) developed independently by HANSON PHARAM. Similarly, in April 2024, Macrogenics’ stock price surged […]

Blog 2024-05-09
DIMA’s progress in popular ADC target projects

Navigating the ADC Frontier: Unleashing the Magic of Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) have been one of the hottest areas in the biopharmaceutical industry in recent years. Pharmaceutical giants such as Pfizer, AbbVie, AstraZeneca, and Merck are investing billions of dollars in breakthrough technologies targeting cancer treatment. According to the latest report from the market intelligence company Evaluate, in 2023, the total value of ADC-focused […]

Blog 2024-04-30
The mechanism of BI905711

CDH17: A Target for Diverse Solid Tumor Therapies—Will It Lead to Significant Breakthroughs in Cancer Treatment?

In March 2022, a study published in Nature Cancer highlighted Cadherin 17 (CDH17) as an ideal target for chimeric antigen receptor (CAR) T-cell therapy in gastrointestinal tumors (including gastric cancer, pancreatic cancer, and colorectal cancer) and neuroendocrine tumors (NETs). CDH17 swiftly gained attention across major news platforms, providing fresh insights into tumor-associated antigens and the […]

Blog 2024-04-19
The structure of Claudin proteins enables the Claudins tight protein family to effectively maintain the polarity of epithelial and endothelial cells.

Tumor Immune Target – Claudin18.2

Since Ganymed unveiled the efficacy data of Zolbetuximab (IMAB362), the anti-Claudin18.2 monoclonal antibody, for the treatment of advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJ) at the 2016 ASCO conference, Claudin18.2 has emerged as a focal point for pharmaceutical companies eager to advance therapeutic options. These companies explore various technological routes, including monoclonal antibodies, bispecific antibodies, […]

Blog , 2024-04-18
The structure of MUC1 gene (A) and protein (B)

MUC1 – What is its Potential in Cancer Therapy?

Mucin1 (MUC1), also known as MAM6 and EMA, is a surface mucin glycoprotein found to be highly expressed in epithelial-derived tumor tissues, such as lung cancer, pancreatic cancer, prostate cancer, epithelial ovarian cancer, and breast cancer. Its expression has been correlated with tumor metastasis and recurrence. Currently, MUC1 has attracted the attention of several pharmaceutical […]

Blog 2024-03-25